BTW, the above director purchase (one of the more substantial one's) occurred early in March - within days of the demise of the competing manufacturer of prilocaine & lidocaine. I wonder if that's a coincidence.
I'm not sure if I should be excited - or if it is yet another disappointing display of lack of candor and possibly even contempt of smaller shareholders.
ACR Price at posting:
5.6¢ Sentiment: None Disclosure: Held
